Bank of America Securities analyst Tim Anderson reiterated a Sell rating on Regeneron (REGN – Research Report) today and set a price target of $547.00.
Tim Anderson has given his Sell rating due to a combination of factors impacting Regeneron’s financial outlook. The primary concern is the anticipated decline in product sales and total revenues, particularly for the Eylea franchise, which is expected to decrease significantly due to the closure of patient assistance funds. This reduction in financial support is projected to lower earnings per share (EPS) by approximately 9% for the first quarter.
Additionally, Anderson has adjusted the price objective for Regeneron to $547, down from $575, reflecting a lower price-to-earnings (P/E) multiple. This adjustment is attributed to weaker earnings visibility and concerns over drug pricing and tariffs. The competitive pressures from biosimilars and other market headwinds are also expected to erode Eylea’s market share faster than anticipated, further contributing to the Sell rating. Despite Regeneron’s strong research and development track record, these near-term challenges overshadow the company’s potential pipeline catalysts.
According to TipRanks, Anderson is a 4-star analyst with an average return of 6.7% and a 63.01% success rate. Anderson covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Eli Lilly & Co, and Gilead Sciences.